MAintenance Therapy With Aromatase Inhibitor in Epithelial Ovarian Cancer (MATAO)
Status:
Recruiting
Trial end date:
2030-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy of addition of letrozole to the
standard maintenance therapy in subjects following a primary diagnosis of Estrogen-receptor
(ER) positive high and low grade epithelial ovarian cancer (including fallopian tube and
primary peritoneal cancer) and subsequent primary treatment surgery and chemotherapy. Half of
the participants will receive to the standard maintenance treatment, letrozole, whilst the
other half receives placebo.
The study's primary hypothesis is that the treatment with letrozole increases progression
free survival in comparison to the maintenance standard treatment (superiority trial).
Phase:
Phase 3
Details
Lead Sponsor:
Swiss Go Trial Group
Collaborators:
AGO Study Group Anticancer Fund, Belgium Arbeitsgemeinschaft Gynaekologische Onkologie Austria Helsana AG Hoffmann-La Roche Krebsliga Schweiz Novartis Pharmaceuticals Reliable Cancer Therapies Stiftung Guido Feger